Toronto-Dominion Bank vs Twist Bioscience Corp — how do they compare? Toronto-Dominion Bank trades at $120.5 (market cap $197.03B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Toronto-Dominion Bank is far larger — about 36.2× Twist Bioscience Corp's market cap, and Toronto-Dominion Bank pays a 2.62% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TD | TWST | |
|---|---|---|
Market Cap | $197.03B | $5.45B |
Sector | Financials | Health |
52-Week High | $124.80 | $102.88 |
52-Week Low | $72.55 | $24.16 |
Dividend Yield | 2.62% | — |
Enterprise Value | — | $5.37B |
Signals from Pluang's Aura AI — not financial advice
TD stock trades at $120.53, down 2.48% today, with a bearish technical signal despite recent earnings beats. The company reported strong Q1 2026 EPS of $1.74, beating expectations of $1.63, continuing a pattern of positive surprises. Revenue growth remains steady, climbing from $56.3B in 2024 to $61.3B in 2025. Analyst consensus is bullish with a $153 price target, though technical indicators show mixed signals with RSI neutral and ADX suggesting weakening trend strength.
TD presents a compelling value opportunity with a P/E of 20.08 and strong profitability metrics including 23.38% net income margin. However, investors face risks from volatile cash flow patterns and increasing debt-to-asset ratios. The stock's 27% upside to analyst targets and consistent dividend payments provide support, but macroeconomic sensitivity and regulatory scrutiny require careful monitoring.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →